Bionoid Pharma, Inc. Acquires AI Maverick Intel

Rhea-AI Summary

Bionoid Pharma (OTC PINK:BINP) has signed a definitive agreement with Stronghold Media Group Corp. to acquire the intellectual property rights of AI Maverick Intel, a revolutionary technology for automated customer acquisition. This AI-powered platform enables companies to efficiently find, engage, nurture, and acquire ideal audiences with minimal human involvement.

As part of its strategic shift towards AI-driven execution, Bionoid has also divested its 100% stake in Medical Magnetics Inc. to Lily Zablotsky for nominal consideration. This move aligns with the company's focus on streamlining operations and leveraging AI for future growth.

Wayne Cockburn, Interim CEO of Bionoid Pharma, expressed excitement about the acquisition, stating it will redefine audience engagement and establish Bionoid as a leader in AI-driven execution.

Positive

• Acquisition of AI Maverick Intel's intellectual property rights
• Potential for improved customer acquisition efficiency and productivity
• Strategic shift towards AI-driven execution and innovation
• Streamlining of operations through divestiture of Medical Magnetics Inc.

Negative

• Divestiture of Medical Magnetics Inc. for nominal consideration may result in loss of potential revenue stream
• Potential integration challenges and costs associated with implementing new AI technology

"Pioneering Fully Automated AI Customer Acquisition"

TORONTO, ON / ACCESSWIRE / August 8, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) announces the signing of a definitive agreement with Stronghold Media Group Corp. ("Stronghold") to acquire the intellectual property rights of AI Maverick Intel, a cutting-edge technology set to revolutionize customer acquisition by enabling companies to find, engage, nurture, and acquire their ideal audiences at high velocity and automated scale.

Revolutionizing Audience Engagement with AI Maverick Intel

AI Maverick Intel is a game-changer in tech acquisitions. Utilizing state-of-the-art AI technology, it redefines how companies identify, reach, and engage their target audiences. The platform's advanced automation capabilities empower businesses to achieve efficient customer acquisition with minimal human involvement, maximizing productivity and precision at every touchpoint.

"We are very excited about this new chapter for Bionoid Pharma," said Wayne Cockburn, Interim CEO of Bionoid Pharma. "By harnessing the transformative power of AI Maverick Intel, we are poised to redefine audience engagement. This acquisition propels us towards a future where companies can seamlessly acquire customers with less data and communication fragmentation. It underscores our unwavering commitment to innovation, sustainable growth, and establishing Bionoid as a leader in AI-driven execution."

A Strategic Divestiture to Focus on Digital Transformation

In alignment with this new strategic direction, Bionoid Pharma has sold its 100% stake in Medical Magnetics Inc. (formerly BIOflex Medical Magnetics Inc.) to Lily Zablotsky for nominal consideration. This move is part of Bionoid's broader strategy of streamlining operations and leveraging AI and automation to drive future growth and innovation.

About AI Maverick Intel

AI Maverick Intel is at the forefront of digital transformation in audience engagement. By leveraging cutting-edge AI and machine learning algorithms, this platform redefines how companies connect and scale communications with their target audiences. Its sophisticated automation capabilities ensure highly efficient and impactful marketing campaigns, driving seamless and automated customer acquisition.

For further information, contact:

Wayne Cockburn, Interim CEO
Phone: (905) 505-0770
bionoidpharma@gmail.com

SOURCE: Bionoid Pharma, Inc.

View the original press release on accesswire.com

FAQ

What is the purpose of Bionoid Pharma's acquisition of AI Maverick Intel?

Bionoid Pharma acquired AI Maverick Intel to revolutionize customer acquisition by enabling automated, efficient identification and engagement of target audiences using advanced AI technology.

How will the AI Maverick Intel acquisition impact Bionoid Pharma's (BINP) business strategy?

The acquisition signals a strategic shift towards AI-driven execution, focusing on innovation and sustainable growth in automated customer acquisition, potentially establishing Bionoid as a leader in this field.

What did Bionoid Pharma (BINP) divest as part of its new strategic direction?

Bionoid Pharma sold its 100% stake in Medical Magnetics Inc. (formerly BIOflex Medical Magnetics Inc.) to Lily Zablotsky for nominal consideration, aligning with its strategy to streamline operations and focus on AI and automation.

When did Bionoid Pharma (BINP) announce the acquisition of AI Maverick Intel?

Bionoid Pharma announced the acquisition of AI Maverick Intel on August 8, 2024, as per the press release.